PMID- 29175324
OWN - NLM
STAT- MEDLINE
DCOM- 20171229
LR  - 20180105
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 495
IP  - 1
DP  - 2018 Jan 1
TI  - Lixisenatide reduces amyloid plaques, neurofibrillary tangles and 
      neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.
PG  - 1034-1040
LID - S0006-291X(17)32293-3 [pii]
LID - 10.1016/j.bbrc.2017.11.114 [doi]
AB  - Type 2 diabetes mellitus (T2DM) has been identified as a high risk factor for 
      Alzheimer's disease (AD). The impairment of insulin signaling has been found in 
      AD brain. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, normalises 
      insulin signaling and acts as a neuroprotective growth factor. We have previously 
      shown that the long-lasting GLP-1 receptor (GLP-1R) agonist lixisenatide plays an 
      important role in memory formation, synaptic plasticity and cell proliferation of 
      rats. In the follow-up study, we analysed the neuroprotective effect and 
      mechanism of lixisenatide, injected for 60 days at 10 nmol/kg i.p. once daily in 
      APP/PS1/tau female mice and C57BL/6J female mice (as control) aged 12 month. The 
      results showed that lixisenatide could reduce amyloid plaques, neurofibrillary 
      tangles and neuroinflammation in the hippocampi of 12-month-old APP/PS1/tau 
      female mice; activation of PKA-CREB signaling pathway and inhibition of p38-MAPK 
      might be the important mechanisms in the neuroprotective function of 
      lixisenatide. The study demonstrated that GLP-1R agonists such as lixisenatide 
      might have the potential to be developed as a novel therapy for AD.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Cai, Hong-Yan
AU  - Cai HY
AD  - Department of Microbiology and Immunology, Shanxi Medical University, 56 Xinjian 
      South Road, Taiyuan, Shanxi Province, 030001, China. Electronic address: 
      yancai1@163.com.
FAU - Yang, Jun-Ting
AU  - Yang JT
AD  - Department of Physiology, Shanxi Medical University, 56 Xinjian South Road, 
      Taiyuan, Shanxi Province, 030001, China. Electronic address: 984647776@qq.com.
FAU - Wang, Zhao-Jun
AU  - Wang ZJ
AD  - Department of Physiology, Shanxi Medical University, 56 Xinjian South Road, 
      Taiyuan, Shanxi Province, 030001, China. Electronic address: 
      wzhaojun1025@126.com.
FAU - Zhang, Jun
AU  - Zhang J
AD  - Department of Physiology, Shanxi Medical University, 56 Xinjian South Road, 
      Taiyuan, Shanxi Province, 030001, China. Electronic address: zj2004081@163.com.
FAU - Yang, Wei
AU  - Yang W
AD  - Department of Physiology, Shanxi Medical University, 56 Xinjian South Road, 
      Taiyuan, Shanxi Province, 030001, China. Electronic address: vividmail@163.com.
FAU - Wu, Mei-Na
AU  - Wu MN
AD  - Department of Physiology, Shanxi Medical University, 56 Xinjian South Road, 
      Taiyuan, Shanxi Province, 030001, China. Electronic address: wmna@163.com.
FAU - Qi, Jin-Shun
AU  - Qi JS
AD  - Department of Physiology, Shanxi Medical University, 56 Xinjian South Road, 
      Taiyuan, Shanxi Province, 030001, China. Electronic address: 
      jinshunqi2009@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171122
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Amyloid beta-Protein Precursor)
RN  - 0 (Glp1r protein, rat)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Peptides)
RN  - 74O62BB01U (lixisenatide)
SB  - IM
MH  - Alzheimer Disease/*drug therapy/*metabolism/pathology
MH  - Amyloid beta-Protein Precursor/genetics
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Encephalitis/*drug therapy/*metabolism/pathology
MH  - Female
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Neurofibrillary Tangles/*drug effects/metabolism/pathology
MH  - Neuroprotective Agents/administration & dosage
MH  - Peptides/*administration & dosage
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Amyloid plaques
OT  - Lixisenatide
OT  - Neurofibrillary tangles
OT  - Neuroinflammation
EDAT- 2017/11/28 06:00
MHDA- 2017/12/30 06:00
CRDT- 2017/11/28 06:00
PHST- 2017/11/11 00:00 [received]
PHST- 2017/11/18 00:00 [accepted]
PHST- 2017/11/28 06:00 [pubmed]
PHST- 2017/12/30 06:00 [medline]
PHST- 2017/11/28 06:00 [entrez]
AID - S0006-291X(17)32293-3 [pii]
AID - 10.1016/j.bbrc.2017.11.114 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2018 Jan 1;495(1):1034-1040. doi: 
      10.1016/j.bbrc.2017.11.114. Epub 2017 Nov 22.